



Annual General Meeting

11 November 2022

FORWARD LOOKING STATEMENTS

Accordingly, these slides and the information they contain should be read in conjunction with past and future announcements made by Medibio Limited and should not be relied upon as an independent source of information. Please contact Medibio Limited and/or refer to the Company's website for further information. The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified.

None of Medibio Limited, or any of its affiliates or associated companies (or any of their officers, employees, contractors or agents (the Relevant Persons)) makes any representation or warranty as to the accuracy, completeness or reliability of the information, or the likelihood of fulfilment of any forward-looking statement or any outcomes expressed or implied in any forward-looking statements.

Any forward-looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside Medibio Limited's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this presentation include known and unknown risks.

The purpose of the presentation is to provide an update of the business of **Medibio Limited (ASX:MEB)**. These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification.

Actual results could differ materially to the assumptions made and Medibio Limited's current intentions, plans, expectations and beliefs about the future. You are urged to view all forward looking statements contained in this presentation with caution. Except as required by applicable law or the ASX listing rules, the Relevant Persons disclaim any obligation or undertaking to publicly update any statements in this presentation, whether as a result of new information or future events.

This presentation should not be relied on as a recommendation or forecast by Medibio Limited. This presentation does not constitute investment advice or should be construed as either an offer to sell, or a solicitation of an offer, to buy or sell shares in any jurisdiction.



Medibio Limited is a health technology Company pioneering the use of objective measures to aid in the early detection and screening of mental health conditions. We offer mental well-being solutions for businesses through our Corporate Health product and are developing products to serve the healthcare provider market.

The Company's focus is based on benchmark research linking heart rate variability and mental health.

By improving upon self-reported assessments, our technology empowers clinicians to aid in early detection of mental health conditions and empowers individuals to screen and better understand their mental wellness.



- **Rebranding**

The naming convention for the Medibio app Luca was in a trademark conflict and as a result will require a rebranding process. This will afford Medibio the opportunity to bring a new, fresh brand for all the products to market. The rebranding, naming conventions process will require 3-4 months and will be commenced this month.

- **Operational Review**

The current staffing and operational structure is being reviewed. There will be staff reductions and realignments as this process moves forward. Reduction in operational costs and streamlining outgoings.

- **Partnership Opportunities**

Medibio will be expending more effort in developing partnership with other entities particularly in the clinical and behavioral health space to increase Medibio's presence in the US and world markets

- **Sales and Marketing**

As the new versions of the Apps are completed and we approach the FDA approval to initiate the sales and marketing programs. These programs need to be initiated several months ahead of any projected revenue

- **Stager**

The current algorithm is being redeployed as a research tool. This is being used as stand-alone data evaluation tool for academic researchers. The pricing model is being refined and is anticipated to provide a modest recurrent revenue source. This will be renamed as part overall rebrand.

- **APPs**

Formerly the naming convention for the app's was Luca and Ilumen. The "New App" is currently being added to and new modules are being developed. The focus is to make this into an App that can be integrated into other behavioral health platforms as well as an employer focused product. This will allow larger more productive sales channels with lower cost of sales. Ilumen is also being redesigned to work in tandem with "New APP".

- **MEB-001**

This is the Medibio's flagship Major Depressive Episode diagnostic application. As part of the rebranding, it will receive a commercial name as part of the family of products. The pricing and deployment design are being developed in conjunction with the FDA approval.

Milestone	Scheduled date
Algorithm Performance Evaluation	December 2022
Engage Potential Commercial Partners	Jan-March 2023
Course Correct on Desktop to API if needed	March 2023
Begin Clinical Validation with Commercial Partner	April 2023
Sales/Revenue*	September 2023

*Expected commercialization for Stager and App's will begin immediately.

EXECUTIVE MANAGEMENT



DR. THOMAS YOUNG
*CEO
M.D.*



ARCHIE DEFILLO
Chief Medical Officer



MASSIMILIANO GRASSI
Head of Artificial Intelligence

BOARD OF DIRECTORS



DAVID TRIMBOLI
*Non-Executive Chair
B.Com*



MELANIE LEYDIN
*Non-Executive Director (CA, FGIA)
Managing Director*



MATT MESNIK
*Non-Executive Director
Chief Medical Officer - Spok*

ADVISORY BOARD



PETER CARLISLE
*Managing Director -
Olympics & Action
Sports at Octagon
Worldwide*



ELIZABETH LOMBARDO, PhD
*Global & Virtual Keynote
Speaker and Author*



JOHN MATHIAS
*Chief Development Officer
MedBridge Healthcare*



MICHAEL PHELPS
Mental Health Advocate



PATRICK KENNEDY
*Former US Congressman
Founder, Kennedy Forum*



Medibio Limited

United States HQ:
8696 Eagle Creek Circle
Savage, MN 55378

Melbourne
Level 4, 100 Albert Road
South Melbourne VIC
3205